US20160331818A1 - Novel antigen peptide and uses thereof - Google Patents
Novel antigen peptide and uses thereof Download PDFInfo
- Publication number
- US20160331818A1 US20160331818A1 US14/963,308 US201514963308A US2016331818A1 US 20160331818 A1 US20160331818 A1 US 20160331818A1 US 201514963308 A US201514963308 A US 201514963308A US 2016331818 A1 US2016331818 A1 US 2016331818A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- hla
- peptides
- antigen
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 269
- 239000000427 antigen Substances 0.000 title claims abstract description 114
- 108091007433 antigens Proteins 0.000 title claims abstract description 114
- 102000036639 antigens Human genes 0.000 title claims abstract description 114
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 38
- 201000011510 cancer Diseases 0.000 claims abstract description 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 46
- 150000001413 amino acids Chemical class 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 17
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 10
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 102100035486 Nectin-4 Human genes 0.000 abstract description 50
- 101710043865 Nectin-4 Proteins 0.000 abstract description 50
- 102000004196 processed proteins & peptides Human genes 0.000 description 94
- 210000004027 cell Anatomy 0.000 description 65
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 31
- 108010075704 HLA-A Antigens Proteins 0.000 description 18
- 102000011786 HLA-A Antigens Human genes 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 16
- 210000004443 dendritic cell Anatomy 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 11
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 11
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 206010033128 Ovarian cancer Diseases 0.000 description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 description 9
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 8
- 108010058607 HLA-B Antigens Proteins 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 8
- 230000005593 dissociations Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 108091054437 MHC class I family Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102100039641 Protein MFI Human genes 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- -1 form amine hydrochlorides Chemical class 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 102000043129 MHC class I family Human genes 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 102000002356 Nectin Human genes 0.000 description 3
- 108060005251 Nectin Proteins 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000047279 human B2M Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000954 titration curve Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WNBBONCQSHHDII-BHFSHLQUSA-N (2s)-2,4-diamino-4-oxobutanoic acid;(2s)-2,5-diamino-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC(=O)[C@@H](N)CCC(N)=O WNBBONCQSHHDII-BHFSHLQUSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000920033 Eugenes Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102210024302 HLA-B*0702 Human genes 0.000 description 1
- 108010078301 HLA-B*07:02 antigen Proteins 0.000 description 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 1
- 101100240352 Homo sapiens NECTIN4 gene Proteins 0.000 description 1
- 101001023705 Homo sapiens Nectin-4 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 108010059255 MAGE-A10 antigen Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000008271 glucosaminides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 108010065889 glycyl-leucyl-cysteinyl-threonyl-leucyl-valyl-alanyl-methionyl-leucine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000043460 human nectin4 Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 108010055094 transporter associated with antigen processing (TAP) Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
Description
- The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
- Over the recent years, the understanding of tumor biology processes lead to the development of targeted therapies like tyrosine kinase inhibitors or monoclonal antibodies. Recent results obtained with monoclonal antibodies validated the immunotherapy approach. Induction of immunity by cancer vaccines is thought to induce immune memory and thereby prevent tumor development. Many immunotherapeutic approaches are aimed to stimulate anti tumor CD8+ CTL responses. New cell surface expressed tumor associated antigens (TAA) that are shared among different tumors and not expressed in normal tissues are attractive candidates for used in vaccines.
- The inventors recently described a new tumor associated antigen named Nectin4 [S. Fabre-Lafay et al., 2007] which have been described as a new TAA in 50%, 49% and 86% of breast, ovarian and lung carcinomas respectively. Moreover, a soluble form of Nectin4 is found in sera of patients and Nectin4 expression is mainly found in tumors with adverse prognosis. These characteristics assigned Nectin4 as a potent candidate for used in vaccination.
- Nectin4 is already known in cancer. For example, patent application WO2004016799 discloses 9mer peptides obtainable from the Nectin4 sequence and their possible use as vaccine against cancer. However, this patent application doesn't disclose experimental results and doesn't give any information about relevant peptides.
- In order to identify new Nectin4 antigens, the inventors have done a multiplex approach aiming to select the most relevant peptide antigen candidate using a combination of biochemical (iTopia Epitope Discovery System), cellular (CEM-T2 cell line) and algorithmic (SYFPEITHI)-based methods.
- The critical steps of this approach are: 1) peptide sequence; 2) demonstration of appropriate processing of the peptide inside cell; 3) peptide binding to the
relevant HLA class 1 orClass 2 molecule; 4) recognition by T cell receptor. - Based on the Nectin4 sequence, the inventors have synthesized all the relevant 9-mer peptides (502). Among all the candidate peptides, they have identified peptides bound with high avidity to HLA-A2, recognized by T cells and finally efficiently processed and presented by tumor cells.
- The study led the inventors to identify a new antigen peptide (SEQ ID NO: 2) named N4-145 that are recognized by HLA-A*0201-restricted CTL.
- Thus, the invention relates to an antigen peptide comprising the amino acids motif:
-
(SEQ ID No 2) VLVPPLPSL, - wherein the peptide may differ from 1, 2 or 3 aminoacids.
- Another object of the invention relates to an expression vector comprising a nucleic acid sequence encoding an antigen peptide according to the invention.
- Another object of the invention relates to a host cell comprising an expression vector according to the invention.
- Another object of the invention relates to an antibody or fragment thereof that binds to the antigen peptide according to the invention.
- Another object of the invention relates to an MHC/peptide multimer comprising an antigen peptide according to the invention.
- Another object of the invention relates to an immunising composition comprising
- (a) at least one antigen peptide according to the invention or
- (b) at least one expression vector according to the invention, or
- (c) at least one host cell according to the invention, or
- (d) at least one antibody according to the invention, or
- (e) at least one nucleic acid sequence that encodes at least one antigen peptide according to the invention.
- Another object of the invention relates to a T lymphocyte that recognizes specifically an antigen peptide according to the invention.
- Another object of the invention relates to a composition for adoptive therapy comprising T lymphocytes according to the invention.
- Another object of the invention relates to a method for producing said T lymphocytes according to the invention, said method comprising the steps of
- (a) stimulating PBMCs or tumor infiltrating lymphocytes obtained from a subject with at least one antigen peptide according to the invention,
- (b) enriching the population of T lymphocytes specific for the antigen peptide(s) used in (a),
- (c) optionally cloning said population of T lymphocytes specific for the antigen peptide(s) used in (a).
- Another object of the invention relates to a method for monitoring a cancer in a subject in need thereof, comprising determining the frequency of T lymphocytes that recognize specifically an antigen peptide according to the invention.
- Throughout the specification, several terms are employed and are defined in the following paragraphs.
- As used herein, the term “Nectin4” denotes a new tumor associated antigen which is a cell surface expressed adhesion molecule and belongs to the nectin family [N. Reymond, et al., 2001 and S. Fabre-Lafay, et al., 2005]. Nectins are widely expressed in tissues and play a key role in different biological processes during development and adult life [Y. Takai et al., 2003, Y. Takai et al., 2008, N. Reymond et al., 2004 N. Takai et al., 2008, and Fournier et al 2010 (med sciences)]. Nectins have been involved in different pathological processes in humans [D. Pende et al., 2005, M. Kuramochi et al., 2001 and F. Brancati et al., 2010]. An exemplary sequence for human nectin4 gene is deposited in the database under accession number AF426163 (SEQ ID NO. 1).
- As used herein, the term “peptide” refers to an amino acid sequence having less than 50 amino acids. As used herein, the term “peptide” encompasses amino acid sequences having less than 50 amino acids, less than 40 amino acids, less than 30 amino acids, less than 25 amino acids, less than 20 amino acids, less than 15 amino acids or less than 10 amino acids.
- As used herein, the term “antibody” refers to a protein capable of specifically binding an antigen, typically and preferably by binding an epitope or antigenic determinant or said antigen. The term “antibody” also includes recombinant proteins comprising the binding domains, as well as variants and fragments of antibodies. Examples of fragments of antibodies include Fv, Fab, Fab′, F(ab′)2, dsFv, scFv, sc(Fv)2, diabodies and multispecific antibodies formed from antibody fragments.
- “Function-conservative variants” as used herein refer to those in which a given amino acid residue in a protein or enzyme has been changed (inserted, deleted or substituted) without altering the overall conformation and function of the polypeptide. Such variants include protein having amino acid alterations such as deletions, insertions and/or substitutions. A “deletion” refers to the absence of one or more amino acids in the protein. An “insertion” refers to the addition of one or more of amino acids in the protein. A “substitution” refers to the replacement of one or more amino acids by another amino acid residue in the protein. Typically, a given amino acid is replaced by an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like). Amino acids other than those indicated as conserved may differ in a protein so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for example, from 70% to 99% as determined according to an alignment scheme such as by the Cluster Method, wherein similarity is based on the MEGALIGN algorithm. A “function-conservative variant” also includes a polypeptide which has at least 60% amino acid identity as determined by BLAST or FASTA algorithms, preferably at least 75%, more preferably at least 85%, still preferably at least 90%, and even more preferably at least 95%, and which has the same or substantially similar properties or functions as the native or parent protein to which it is compared. Two amino acid sequences are “substantially homologous” or “substantially similar” when greater than 80° A, preferably greater than 85%, preferably greater than 90% of the amino acids are identical, or greater than about 90%, preferably greater than 95%, are similar (functionally identical) over the whole length of the shorter sequence. Preferably, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package,
Version 7, Madison, Wis.) pileup program, or any of sequence comparison algorithms such as BLAST, FASTA, etc. - The term “Major Histocompatibility Complex” (MHC) is a generic designation meant to encompass the histo-compatibility antigen systems described in different species including the human leucocyte antigens (HLA).
- The term “breast cancer” as used herein includes, but is not limited to, all types of breast cancers at all stages of progression like metastatic breast cancer or breast carcinomas.
- The term “ovarian cancer” as used herein includes, but is not limited to, all types of ovarian cancers at all stages of progression like metastatic ovarian cancer or ovarian carcinomas.
- The term “lung cancer” as used herein includes, but is not limited to all types of lung cancers at all stages of progression like lung carcinomas metastatic lung cancer, non-small cell lung carcinomas or Small cell lung carcinoma.
- The term “treating” a disorder or a condition refers to reversing, alleviating or inhibiting the process of one or more symptoms of such disorder or condition. The term “preventing” a disorder or condition refers to preventing one or more symptoms of such disorder or condition.
- As used herein, the term “subject” denotes a mammal, such as a rodent, a feline, a canine, and a primate. Preferably a subject according to the invention is a human.
- A “therapeutically effective amount” as used herein is intended for a minimal amount of active agent which is necessary to impart therapeutic benefit to a subject. For example, a “therapeutically effective amount of the active agent” to a subject is an amount of the active agent that induces, ameliorates or causes an improvement in the pathological symptoms, disease progression, or physical conditions associated with the disease affecting the subject.
- The term “adjuvant” as used herein refers to a compound or a mixture that may be non-immunogenic when administered in the host alone, but that augments the host's immune response to an antigen when administered conjointly with that antigen.
- A first object of the invention relates to an antigen peptide comprising the amino acids motif:
-
(SEQ ID NO: 2) VLVPPLPSL - wherein the peptide may differ from 1, 2 or 3 aminoacids.
- In one embodiment of the invention, by “antigen peptide” is meant a peptide capable of binding to HLA molecule and causing a cellular or humoral response in a subject.
- In a preferred embodiment of the invention, said antigen peptide may comprise a specific motif such that the polypeptide binds an HLA molecule and induces a CTL response.
- In another preferred embodiment of the invention, said antigen peptide may comprise a specific motif such that the polypeptide binds an HLA molecule and induces a helper T cell response.
- In another embodiment of the invention, said antigen peptides as described here above are HLA-A*0201 restricted.
- In one embodiment of the invention, said antigen peptide is an amino acid sequence of less than 50 amino acids long that comprises the amino acid motif SEQ ID NO: 2 as defined here above.
- In another embodiment of the invention, said antigen peptide is an amino acid sequence of less than 45 amino acids long that comprises the amino acid motif SEQ ID NO: 2 as defined here above.
- In another embodiment of the invention, said antigen peptide is an amino acid sequence of less than 40 amino acids long that comprises the amino acid motif SEQ ID NO: 2 as defined here above.
- In another embodiment of the invention, said antigen peptide is an amino acid sequence of less than 30 amino acids long that comprises the amino acid motif SEQ ID NO: 2 as defined here above.
- In another embodiment of the invention, said antigen peptide is an amino acid sequence of less than 20 amino acids long that comprises the amino acid motif SEQ ID NO: 2 as defined here above.
- In another embodiment of the invention, said antigen peptide is an amino acid sequence of less than 15 amino acids long that comprises the amino acid motif SEQ ID NO: 2 as defined here above.
- In another embodiment of the invention, said antigen peptide is an amino acid sequence of 10 or 11 amino acids long that comprises the amino acid motif SEQ ID NO: 2 as defined here above.
- The invention also encompasses peptides that are function-conservative variants of antigen peptides comprising SEQ ID NO: 2 as described here above.
- Typically, the invention encompasses peptides substantially identical to antigen peptides comprising SEQ ID NO: 2 in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the functional aspects of the antigen peptides comprising SEQ ID NO: 2 as described here above, i.e. being still able to bind to an HLA molecule in substantially the same way as a peptide consisting of the given amino acid sequence.
- Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another, the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid or another.
- The term “conservative substitution” also includes the use of a chemically derivatized residue in place of a non-derivatized residue. “Chemical derivative” refers to a subject peptide having one or more residues chemically derivatized by reaction of a functional side group. Examples of such derivatized molecules include for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Chemical derivatives also include peptides which contain one or more naturally-occurring amino acid derivatives of the twenty standard amino acids. For examples: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine.
- According to the invention, the antigen peptides of the invention can be obtained by synthesizing the peptides according to the method for peptide synthesis known in the art.
- In another embodiment, the antigen peptides of the invention may be incorporated into polytopes. Two or more peptides of the invention can be joined together directly, or via the use of flanking sequences. Thompson et al., Proc. Natl. Acad. Sci. USA 92 (13): 5845-5849 (1995), teaches the direct linkage of relevant epitopic sequences. The use of polytopes as vaccines is well known. See. e.g. Gilbert et al., Nat. Biotechnol. 15 (12): 1280-1284 (1997); Thomson et al., supra; Thomson et al., J. Immunol. 157 (2): 822-826 (1996); Tam et al., J. Exp. Med. 171 (1): 299-306 (1990), all of which are incorporated by reference. The Tam et al. reference in particular shows that polytopes, when used in a mouse model, are useful in generating both antibody and protective immunity.
- In another embodiment, the antigen peptide according to the invention may be use in the prevention or treatment of cancer.
- In a preferred embodiment, cancer may be selected from the group consisting of breast, ovarian or lung cancer.
- Another object of the invention is an expression vector comprising a nucleic acid sequence encoding an amino sequence comprising SEQ ID NO: 2 as described here above.
- In one embodiment of the invention, said expression vector comprises the nucleic acid sequence corresponding to the open reading frame 433 to 459 of SEQ ID NO: 1.
- According to the invention, expression vectors suitable for use in the invention may comprise at least one expression control element operationally linked to the nucleic acid sequence. The expression control elements are inserted in the vector to control and regulate the expression of the nucleic acid sequence. Examples of expression control elements include, but are not limited to, lac system, operator and promoter regions of phage lambda, yeast promoters and promoters derived from polyoma, adenovirus, retrovirus, lentivirus or SV40. Additional preferred or required operational elements include, but are not limited to, leader sequence, termination codons, polyadenylation signals and any other sequences necessary or preferred for the appropriate transcription and subsequent translation of the nucleic acid sequence in the host system. It will be understood by one skilled in the art that the correct combination of required or preferred expression control elements will depend on the host system chosen. It will further be understood that the expression vector should contain additional elements necessary for the transfer and subsequent replication of the expression vector containing the nucleic acid sequence in the host system. Examples of such elements include, but are not limited to, origins of replication and selectable markers. It will further be understood by one skilled in the art that such vectors are easily constructed using conventional methods or commercially available.
- Another object of the invention is a host cell comprising an expression vector as described here above.
- According to the invention, examples of host cells that may be used are eukaryote cells, such as animal, plant, insect and yeast cells and prokaryotes cells, such as E. coli. The means by which the vector carrying the gene may be introduced into the cells include, but are not limited to, microinjection, electroporation, transduction, or transfection using DEAE-dextran, lipofection, calcium phosphate or other procedures known to one skilled in the art.
- In a preferred embodiment, eukaryotic expression vectors that function in eukaryotic cells are used. Examples of such vectors include, but are not limited to, viral vectors such as retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, poxvirus, poliovirus; lentivirus, bacterial expression vectors, plasmids, such as pcDNA3 or the baculovirus transfer vectors. Preferred eukaryotic cell lines include, but are not limited to, COS cells, CHO cells, HeLa cells, NIH/3T3 cells, 293 cells (ATCC# CRL1573), T2 cells, dendritic cells, or monocytes.
- Another object of the invention relates to an antibody or fragment thereof that binds to the antigen peptide according to invention.
- In one embodiment of the invention, said antibody or fragment thereof binds to the peptide of SEQ ID NO: 2.
- In one embodiment of the invention, said antibody is monoclonal. In another embodiment of the invention, said antibody is polyclonal.
- Such antibodies may be easily prepared, for example, according to the method described in “Antibodies: A laboratory manual”, Lane H. D. et al. eds, Cold Spring Harbor Laboratory Press, New York, 1989 or Antibody Engineering: Methods and Protocols, 2003, Benny K. Lo.
- Another object of the invention is a MHC/peptide multimer comprising an antigen peptide as described here above. According to the invention, said MHC/peptide multimer include, but are not limited to, a MHC/peptide dimer, trimer, tetramer or pentamer.
- In one embodiment of the invention, said MHC/peptide multimer is a HLA-A*0201/peptide multimer.
- Methods for obtaining MHC/peptide tetramers are described in WO96/26962 and WO01/18053, which are incorporated by reference.
- In one embodiment of the invention, said MHC/peptide multimer can be used to visualise T cell populations that are specific for the complex HLA-A*0201/antigen peptide as described here above.
- In another embodiment of the invention, said MHC/peptide multimer can be used for the detection and/or isolation by screening (in flow cytometry or by immunomagnetic screening) of T cell population that are specific for a complex HLA/antigen peptide as described here above.
- In another embodiment of the invention, said HLA-A*0201/peptide multimer can be used for the detection and/or isolation by screening (in flow cytometry or by immunomagnetic screening) of T cell population that are specific for a complex HLA-A*201/antigen peptide as described here above.
- Another object of the invention is beads coated with MHC/peptide multimers as described here above.
- Another object of the invention is an immunising composition comprising
- (a) at least one antigen peptide as described here above or
- (b) at least one expression vector as described here above, or
- (c) at least one host cell as described here above, or
- (d) at least one antibody as described here above, or
- (e) at least one nucleic acid sequence that encodes at least one antigen peptide as described here above.
- In one embodiment, said immunising composition comprises the antigen peptide N4-145 having the sequence SEQ ID NO: 2.
- The prophylactic administration of the immunising composition of the invention should serve to prevent or attenuate cancer in a mammal. In a preferred embodiment mammals, preferably human, at high risk for cancer are prophylactically treated with the immunising composition of the invention. Examples of such mammals include, but are not limited to, humans with a family history of cancer.
- When provided therapeutically, the immunising composition of the invention is provided to enhance the patient's own immune response to the cancer antigen present on the cancer or metastatic cancer.
- In one embodiment of the invention, the peptides of the invention may be conjugated with lipoprotein or administered in liposomal form or with adjuvant.
- In one embodiment, said immunising composition is a pharmaceutical composition.
- In such embodiment, said immunising composition, for human use, comprises at least one antigen peptide as described here above or at least one antibody as described here above, together with one or more pharmaceutically acceptable carriers and, optionally, other therapeutic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof. The immunising compositions may conveniently be presented in unit dosage form and may be prepared by any method well-known in the pharmaceutical art.
- Immunising compositions suitable for intravenous, intradermal, intramuscular, subcutaneous, or intraperitoneal administration conveniently comprise sterile aqueous solutions of the active agent with solutions which are preferably isotonic with the blood of the recipient. Such compositions may be conveniently prepared by dissolving solid active ingredient in water containing physiologically compatible substances such as sodium chloride (e.g. 0.1-2.0M), glycine, and the like, and having a buffered pH compatible with physiological conditions to produce an aqueous solution, and rendering said solution sterile. These may be present in unit or multi-dose containers, for example, sealed ampoules or vials.
- The immunising compositions of the invention may incorporate a stabilizer. Illustrative stabilizers are polyethylene glycol, proteins, saccharides, amino acids, inorganic acids, and organic acids which may be used either on their own or as admixtures. These stabilizers are preferably incorporated in an amount of 0.11-10,000 parts by weight per part by weight of active agent. If two or more stabilizers are to be used, their total amount is preferably within the range specified above. These stabilizers are used in aqueous solutions at the appropriate concentration and pH. The specific osmotic pressure of such aqueous solutions is generally in the range of 0.1-3.0 osmoles, preferably in the range of 0.8-1.2. The pH of the aqueous solution is adjusted to be within the range of 5.0-9.0, preferably within the range of 6-8.
- Additional pharmaceutical methods may be employed to control the duration of action. Controlled release preparations may be achieved through the use of polymer to complex or absorb the peptides of the invention. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyester, polyamirio acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release. Another possible method to control the duration of action by controlled-release preparations is to incorporate the antigen peptides of the invention into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylaceiate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxy-methylcellulose or gelatin-microcapsules and poly(methylmethacylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions.
- When oral preparations are desired, the compositions may be combined with typical carriers, such as lactose, sucrose, starch, talc magnesium stearate, crystalline cellulose, methyl cellulose, carboxymethyl cellulose, glycerin, sodium alginate or gum arabic among others.
- Immunisation of a subject with the immunising composition of the invention can be conducted by conventional methods, for example, in the presence of conventional adjuvants. Examples of conventional adjuvant include, but are not limited to, metal salts, oil in water emulsions, Toll like receptors agonists, saponins, lipid A, alkyl glucosaminide phosphate, Freund's adjuvant, keyhole limpet haemocyanin (KLH), mannan, BCG, alum, cytokines such as IL-1, IL-2, macrophage colony stimulating factor, and tumor necrosis factor; and other substances that act as immunostimulating agents such as muramyl peptides or bacterial cell wall components, toxins, toxoids and TLR ligands.
- The immunising composition can be administered by any route appropriate for antibody production and/or T cell activation such as intravenous, intraperitoneal, intramuscular, subcutaneous, and the like. The immunising composition may be administered once or at periodic intervals until a significant titre of anti-Nectin4 immune cells or anti-Nectin4 antibody is produced. The presence of anti-Nectin4 immune cells may be assessed by measuring the frequency of precursor CTL (cytoxic T-lymphocytes) against the antigen peptides of the invention prior to and after immunization by specific tetramer labelling or by a CTL precursor analysis assay. The antibody may be detected in the serum using an immunoassay.
- Antibodies directed to the antigens of the invention can also be used directly as anti-cancer agents. To prepare antibodies, a host animal may be immunized using the Nectin4 protein or others antigen peptides as described here above. The host serum or plasma is collected following an appropriate time to provide a composition comprising antibodies reactive to said antigen peptides. The gamma globulin fraction or the IgG antibodies can be obtained, for example, by use of saturated ammonium sulfate or DEAE Sephadex, or other techniques known to those skilled in the art. The antibodies are substantially free of many of the adverse side effects which may be associated with other anti-cancer agents such as chemotherapy.
- The immunising composition of the invention comprising antibodies as described here above can be made even more compatible with the host system by minimizing potential adverse immune system responses. This is accomplished by removing all or a portion of the Fc portion of a foreign species antibody or using an antibody of the same species as the host subject, for example, the use of antibodies from human/human hybridomas. Humanized antibodies (i.e., nonimmunogenic in a human) may be produced, for example, by replacing an immunogenic portion of an antibody with a corresponding, but nonimmunogenic portion (i.e., chimeric antibodies). Such chimeric antibodies may contain the reactive or antigen binding portion of an antibody from one species and the Fc portion of an antibody (nonimmunogenic) from a different species. Examples of chimeric antibodies, include but are not limited to, nonhuman mammal-human chimeras, rodent-human chimeras, murine-human and rat-human chimeras.
- Methods for obtaining said antibodies, chimeric antibodies and humanized chimeric antibodies are well-known in the art.
- The immunising composition comprising the antibodies of the invention can also be used as a means of enhancing the immune response. The antibodies can be administered in amounts similar to those used for other therapeutic administrations of antibody. For example, pooled gamma globulin is administered at a range of about 1 mg to about 100 mg per subject. Thus, antibodies reactive with the antigen peptides of the invention can be passively administered alone or in conjunction with other anti-cancer therapies to a mammal afflicted with cancer. Examples of anti-cancer therapies include, but are not limited to, chemotherapy, radiation therapy, adoptive immunotherapy therapy with TIL.
- The antibodies or chimeric antibodies described herein may also be coupled to toxin molecules, radioisotopes and drugs by conventional methods. Examples of toxins to which the antibodies may be coupled to included, but are not limited to, ricin or diphtheria toxin. Examples of drugs or chemotherapeutic agents include, but are not limited to, cyclophosphamide or doxorubicin. Examples of radioisotopes, include, but are not limited to, 1311. Antibodies covalently conjugated to the aforementioned agents can be used in cancer immunotherapy for treating cancer.
- If the subject to be immunized is already afflicted with cancer or metastatic cancer, the immunising composition of the invention can be administered in conjunction with other therapeutic treatments. Examples of other therapeutic treatments includes, but are not limited to, adoptive T cell immunotherapy, coadministration of cytokines or other therapeutic drugs for cancer.
- The dose of antigen peptide of the invention to be administered to a subject may be adjusted as appropriate depending on, for example, the disease to be treated, the age and the body weight of said subject. Ranges of antigen peptides of the invention that may be administered are about 0.001 to about 100 mg per subject, preferred doses are about 0.01 to about 10 mg per subject.
- The immunising composition of the invention may be evaluated first in animal models, initially rodents, and in nonhuman primates and finally in humans. The safety of the immunization procedures is determined by looking for the effect of immunization on the general health of the immunized animal (weight change, fever, appetite behavior etc.) and looking for pathological changes on autopsies. After initial testing in animals, cancer patients can be tested. Conventional methods would be used to evaluate the immune response of the patient to determine the efficiency of the immunising composition.
- Another object of the invention is an immunising composition comprising
- (a) at least one antigen peptide as described here above or
- (b) an expression vector comprising a nucleic acid sequence encoding a antigen peptide defined in (a) as described here above, or
- (c) a host cell comprising an expression vector defined in (b) as described here above, or
- (d) an antibody that recognizes specifically a antigen peptide defined in (a) as described here above, or
- (e) at least one nucleic acid encoding at least one antigen peptide of the invention,
- for preventing or treating cancer in a subject in need thereof.
- In one embodiment, the cancer may be breast, ovarian or lung cancer.
- Another object of the invention is an antigen presenting cell comprising a complex HLA antigen and an antigen peptide of the invention.
- In one embodiment of the invention, said complex HLA antigen is a HLA-A*0201 antigen.
- In one embodiment of the invention, said antigen presenting cell is derived from the subject to be treated.
- The term “antigen presenting cell” (APCs) refers to any cell that expresses an HLA antigen capable of presenting the antigen peptide of the invention on its surface. Dendritic cells, which are reported to have an especially high antigen-presenting ability, are preferred. In another embodiment, artificial APCs may also be used such mammalian cells (fibroblast, endothelial cells, keratinocytes), insect cells, or cell lines.
- In order to prepare such APCs of the invention, cells having an antigen-presenting ability are isolated from the subject to be treated, and pulsed ex vivo with at least one antigen peptide of the invention to form a complex with the HLA-A*0201 antigen.
- In case dendritic cells are used, the APC of the invention can be prepared as follows. Lymphocytes are isolated from peripheral blood of the subject to be treated by Ficoll method; adherent cells are separated from non-adherent cells; the adherent cells are then cultured in the presence of GM-CSF and IL-4 to induce dendritic cells; and the dendritic cells are pulsed by culturing with at least one antigen peptide of the invention to obtain the APCs of the invention. The dendritic cells should be exposed to the antigen peptide for sufficient time to allow the antigens to be internalized and presented on the dendritic cells surface. The resulting dendritic cells can then be re-administrated to the subject to be treated. Such methods are described in WO93/208185 and EP0563485, which are incorporated by reference.
- Another object of the invention is a composition for active immunotherapy comprising antigen presenting cells comprising a complex HLA antigen and an antigen peptide of the invention.
- In one embodiment of the invention, said antigen presenting cells comprise a complex HLA-A*0201 antigen and a antigen peptide of the invention.
- Said APCs may be preferably contained in physiological saline, phosphate buffered saline (PBS), culture medium, or the like. Administration may be achieved, for example, intravenously, hypodermically, or intradermally.
- Another object of the invention is a T lymphocyte that recognizes specifically the antigen peptide of the invention.
- In one embodiment of the invention, said T lymphocyte is a cytotoxic T lymphocyte.
- In another embodiment of the invention, said T lymphocyte is HLA-A*0201 restricted.
- In another embodiment of the invention, said T lymphocyte is a T cell clone.
- In another embodiment, said T lymphocyte is a genetically modified T lymphocyte that expresses a TCR that recognizes specifically the antigen peptide of the invention.
- Another object of the invention is a composition for adoptive therapy comprising said T lymphocytes as described here above that recognizes specifically the antigen peptide of the invention.
- In the case of cancer, and preferable in breast, ovarian or lung cancer, it has been observed that an adoptive immunotherapy wherein intratumoral T cell infiltrate taken from the subject to be treated are cultured ex vivo in large quantities, and then returned into the patient achieves a therapeutic gain.
- It is preferred that the T cells are contained in physiological saline, phosphate buffered saline (PBS), culture medium, or the like in order to their stable maintain. Administration may be achieved, for example, intravenously or intra-tumoraly. By returning the T cells that recognizes specifically the antigen peptide of the invention into the subject's body, the toxicity of said T cells on tumor cells is enhanced in the patient who is positive for Nectin4. The tumor cells are destroyed and thereby the treatment of tumor is achieved.
- Examples of where T-lymphocytes can be isolated, include but are not limited to, peripheral blood cells lymphocytes (PBL), lymph nodes, or tumor infiltrating lymphocytes (TIL).
- Such lymphocytes can be isolated from tumor or peripheral blood of the individual to be treated by methods known in the art and cultured in vitro. Lymphocytes are cultured in media such as RPMI or RPMI 1640 for 2-5 weeks, preferably for 2-3 weeks. Viability is assessed by trypan blue dye exclusion assay. The lymphocytes are exposed to the antigen peptide of the invention for all of the culture duration.
- In a preferred embodiment the lymphocytes are exposed to the antigen peptide of the invention at a concentration of about 1 to about 10 micrograms(n)/ml per 107 cells for all the duration of lymphocyte culture. Cytokines may be added to the lymphocyte culture such as IL-2.
- The antigen peptide of the invention may be added to the culture in presence of antigen presenting cells such as dendritic cells or allogeneic irradiated cancer cell line cells.
- After being sensitized to the peptide, the T-lymphocytes are administered to the subject in need of such treatment.
- Examples of how these sensitized T-cells can be administered to the mammal include but are not limited to, intravenously, intraperitoneally or intralesionally. Parameters that may be assessed to determine the efficacy of these sensitized T-lymphocytes include, but are not limited to, production of immune cells in the subject being treated or tumor regression. Conventional methods are used to assess these parameters. Such treatment can be given in conjunction with cytokines or gene modified cells (Rosenberg, S. A. et al. (1992) Human Gene Therapy, 3: 75-90; Rosenberg, S. A. et al. (1992) Human Gene Therapy, 3: 57-73).
- Another object of the invention is a method for producing T lymphocytes that recognize specifically an antigen peptide of the invention, said method comprising the steps of:
- (a) stimulating peripheral blood mononuclear cells (PBMCs) or tumor infiltrating lymphocytes (TIL) obtained from a subject with at least one antigen peptide of the invention,
- (b) enriching the population of T lymphocytes specific for the antigen peptide(s) used in (a),
- (c) optionally cloning said population of T lymphocytes specific for the antigen peptide(s) used in (a).
- Enrichment and/or cloning may be carried out by using an MHC/peptide multimer as described here above. Cloning may also be carried out by conventional methods.
- In one embodiment of the invention, the T lymphocytes that recognize specifically an antigen peptide of the invention are HLA-A*0201 restricted. In such embodiment, enrichment and/or cloning may be carried out by using an HLA-A*0201/peptide multimer as described here above.
- Stimulation of PBMCs may be carried out with at least one antigen peptide of the invention alone, or presented by an antigen presenting cell such as dendritic cells or allogeneic irradiated cancer cell line cells. Typically, cytokines such as IL-2 may also be added to the culture.
- Another object of the invention is a composition for adoptive therapy that comprises lymphocytes that recognizes specifically the antigen peptide of the invention for preventing or treating cancer in a subject in need thereof, wherein said T lymphocytes are to be re-administrated to the subject.
- In one embodiment, the cancer may be breast, ovarian or lung cancer.
- In one embodiment, said lymphocytes that recognizes specifically the antigen peptide of the invention are HLA-A*0201 restricted.
- The invention also relates to a method for treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of
- (a) at least one antigen peptide as described here above or
- (b) an expression vector as described here above, or
- (c) a host cell as described here above, or
- (d) an antibody as described here above, or
- (e) at least one nucleic acid encoding at least one antigen peptide of the invention.
- The invention also relates to a method for treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of T lymphocytes that recognizes specifically the antigen peptide of the invention. In one embodiment, said T lymphocytes are HLA-A*0201 restricted.
- The invention also relates to a method for treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of antigen presenting cells comprising a complex HLA antigen and a antigen peptide of the invention. In one embodiment, said complex HLA/peptide is a complex HLA-A*0201/antigen peptide of the invention.
- Another object of the invention is a method for monitoring a cancer, especially an ovarian, breast or lung cancer in a subject in need thereof, comprising determining the frequency of T lymphocytes that recognize specifically a antigen peptide of the invention.
- In one embodiment of the invention, said T lymphocytes are HLA-A*0201 restricted.
- In one embodiment of the invention, the frequency of T lymphocytes that recognize specifically an antigen peptide of the invention may be determined by using an MHC/peptide multimer as described here above.
- According to the invention, an increase in the frequency of T lymphocytes that recognize specifically an antigen peptide of the invention correlates with relapse prevention.
- Another object of the invention is a kit comprising:
-
- an antibody that recognizes specifically the antigen peptide and/or
- primers or probes for Nectin4 mRNA detection, and/or
- an MHC/peptide multimer comprising a antigen peptide of the invention.
- In one embodiment, said kit further comprises a solid support, wherein said solid support is selected from the group consisting of wells of reaction trays, test tubes, polystyrene beads, strips, membranes and microparticles.
- In another embodiment, said kit further comprises a label, wherein said label is selected in the group consisting of enzymes, radioisotopes, fluorescent compounds and chemiluminescent compounds.
- The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
-
FIG. 1 : Frequency of peptide binding to 8 HLA alleles. The 502 nonamers overlapping by 8 aa, were tested in the iTopia EDS system. Cut-off values were as defined by the manufacturer. -
FIGS. 2A-2D : Off-rates and binding curves for selected peptides binding HLA-A* 0201. - The number associated with peptides represent where the peptide starts in the protein sequence. Curves are fitted using the Graphpad's Prism software. A: Peptide titration curves for selected nectin4 peptides, B: Peptide titration curves for reference peptides, C: Off-rate curves for selected nectin4 peptide, D: Off-rate curves for reference peptides.
-
FIGS. 3A-3D : HLA stabilization assay using the CEMT2 cell line was assessed by flow cytometry. Examples of binding and dissociation histograms of Nectin4 and HBV positive control. - Binding of peptide 145 (white histogram), peptide 122 (grey histogram) or no peptide (dotted histogram) (A) and HBV positive control peptide (white histogram) (B). Kinetic of dissociation for peptide 145 (C) and HBV positive control peptide (D). T0h (solid line), T1h (dotted line), T4h (dashed line), peptide 122 (grey histogram).
-
FIGS. 4A-4F : Characterization of anti-nectin4 CTL derived from healthy PBMC donors. - Labeling of
CTL 21 andCTL 145 with HLA-A2/Nectin4 tetramers loaded with peptide 21 (A) and peptide 145 (B).CTL 21 andCTL 145 mediated lysis of HLA-A2 nectin4 negative MDA-MB-231 target cells loaded or not with Nectin4 peptide 21 (4C) or peptide 145 (4E) respectively.CTL 21 andCTL 145 mediated lysis of HLA-A2 nectin4 expressing MDA-MB-231 target cells loaded or not with Nectin4 peptide 21 (4D) or peptide 145 (4F) respectively. -
FIGS. 5A-5B : Characteristics of N4-145 peptide. - A: Nectin4 is a type-I transmembrane glycoprotein that belongs to the immunoglobulin superfamily. Nectin4 exhibits 3 Ig-like domains of V, C, C type in the extracellular region. Peptide N4-145 localized at the edge of the second Ig-like type C domain. Transmembrane region is in grey. B: Characteristics of N4-145 peptide for the 8 different HLA alleles.
-
TABLE 1 List of control peptides used in the study. Peptide No Sequence Origin SEQ ID NO 503 NLSASVATV Proteinase3 3 513 SLLMWITQV NY-ESO-1 4 514 LYVDSLFFL PRAME 5 515 KVAELVHFL MAGE- A3 6 516 ASSTLYLVF MAGE- C2 7 517 GLYDGMEHL MAGE- A10 8 518 ALKDVEERV MGAE- C2 9 519 YMDGTMSQV Tyrosinase 10 520 VLPDVFIRC GnTV 11 - All these peptides have been referenced and validated as naturally processed and recognized by specific CTL. Some of these control peptides are used in pre-clinical or clinical settings. These peptides were selected to compare with selected nectin4 peptides in the different assays.
-
TABLE 2 Selection and binding characteristics of the 22 high rank HLA-A2 nectin4 peptides based on iTopia analysis. Peptide SEQ % T½ Value Affinity Rank No ID NO Sequence Binding (Hours) (ED50) iScore 1 238 12 HILHVSFLA 87 6.7 6.00E-08 1.426 2 355 13 VIAALLFCL 59 5.2 3.00E-08 0.888 3 354 14 GVIAALLFC 61 6.2 9.00E-08 0.845 4 80 15 ALLHSKYGL 87 7.8 1.00E-06 0.815 5 351 16 VVVGVIAAL 58 3.4 3.00E-08 0.784 6 145 2 VLVPPLPSL 67 7.4 5.00E-07 0.783 7 21 17 LLASFTGRC 91 6 6.00E-07 0.727 8 358 18 ALLFCLLVV 53 6.1 2.00E-07 0.71 9 347 19 SASVVVVGV 64 3.7 2.00E-07 0.708 10 215 20 SMNGQPLTC 81 6.8 7.00E-07 0.689 11 359 21 LLFCLLVVV 67 7.4 5.00E-07 0.674 12 266 22 AMLKCLSEG 74 6.8 7.00E-07 0.667 13 137 23 FQARLRLRV 69 7.3 8.00E-07 0.66 14 19 24 LLLLASFTG 75 2.1 6.00E-08 0.659 15 345 25 LVSASVVVV 51 2.3 6.00E-08 0.626 16 357 26 AALLFCLLV 56 3.8 1.00E-07 0.619 17 35 27 GTSDVVTVV 63 2.9 3.00E-07 0.539 18 255 28 DQNLWHIGR 62 5.4 5.00E-07 0.539 19 244 29 FLAEASVRG 78 2.8 7.00E-07 0.533 20 203 30 AVTSEFHLV 64 3.5 4.00E-07 0.533 21 443 31 RSYSTLTTV 68 2.4 3.00E-07 0.521 22 239 32 ILHVSFLAE 61 2.3 2.00E-07 0.51 -
TABLE 3 Summary of iTopia, CEM T2, SYFPEITHI and BIMAS data obtained for the 22 Nectin4 peptides with iScore ≧ 0.50. CEM.T2 Peptide SEQ iTopia % % Residual Algorithms No Sequence ID NO iScore Binding Binding SYFPEITHI BIMAS 19 LLLLASFTG 24 0.659 17 0 16 2 21 LLASFTGRC 17 0.727 44 86 17 4 35 GTSDVVTVV 27 0.539 60 0 20 3 80 ALLHSKYGL 15 0.815 53 86 26 79 137 FQARLRLRV 23 0.66 30 72 13 32 145 VLVPPLPSL 2 0.783 76 54 31 83 203 AVTSEFHLV 30 0.533 48 0 16 11 215 SMNGQPLTC 20 0.689 21 0 16 3 238 HILHVSFLA 12 1.426 37 66 14 0 239 ILHVSFLAE 32 0.51 10 0 14 0 244 FLAEASVRG 29 0.533 12 0 17 1 255 DQNLWHIGR 28 0.539 6 0 1 0 266 AMLKCLSEG 22 0.667 31 39 18 0 345 LVSASVVVV 25 0.626 11 0 22 9 347 SASVVVVGV 19 0.708 40 0 23 2 351 VVVGVIAAL 16 0.784 82 50 24 7 354 GVIAALLFC 14 0.845 10 0 12 5 355 VIAALLFCL 13 0.888 18 24 26 66 357 AALLFCLLV 26 0.619 15 18 20 13 358 ALLFCLLVV 18 0.71 26 26 28 242 359 LLFCLLVVV 21 0.674 7 23 30 412 443 RSYSTLTTV 31 0.521 37 0 17 3 -
TABLE 4 Ranking of the best five nectin4 peptides selected on the basis of the F-score (iTopia and CEM T2). Comparison with reference peptides listed in table 1. RANK F-Score No Peptide SEQ ID NO 1 520 (GnTV) 11 2 513 (NY-ESO-1) 4 3 519 (Tyrosinase) 10 4 80 15 5 351 16 6 145 2 7 238 12 8 517 (MAGE-A10) 8 9 503 (PR3) 3 10 515 (MAGE-A3) 6 11 21 17 - Cell Lines
- MDA-MB-231 breast carcinoma cell line (ATCC, Manassas) was cultivated in DMEM supplemented with 10% fetal calf serum, 50 IU/ml penicillin, 50 μg/ml streptomycin, and 2 mM glutamine. Cells were cultivated in a 5% CO2 atmosphere at constant humidity. The MDA-MB-231 nectin4 cell line was obtained after transfection with the p3XFLR4.C1 [S. Fabre et al, 2002].
- The Epstein Barr Virus-transformed B (EBV-B) cell lines were cultured in IMDM supplemented with 10% fetal calf serum, with 0.24 mM L-asparagine, 0.55 mM L-arginine, 1.5 mM L-glutamine (AAG), 100 U/ml penicillin and 100 μg/ml streptomycin. Human recombinant IL-2 was purchased from Novartis. Human recombinant IL-4, IL-7 and GM-CSF were from R&D Systems, MN, USA.
- Peptides
- A library of 502 nonapeptides which span the entire 510 amino acid sequence of human nectin4, was synthesized (JPT Peptide Technologies GmbH, Berlin Germany). A series of 9 peptides described in the literature was selected and used as reference (Table 1). Peptides (purity >80%) were dissolved in DMSO at a concentration of 10 mM and stored at −20° C. Specific control peptides for each allele were supplied by the manufacturer of the iTopia Epitope Discovery System (EDS) (Beckman Coulter Inc., San Diego, Calif., USA). The 502 peptides were tested for binding to eight alleles (HLA-A*0101; HLA-A*0201; HLA-A*0301; HLA-A*1101; HLA-A*2402; HLA-A*0702; HLA-B*0801; HLA-B*1501) with the iTopia EDS.
- MHC Peptide Binding Assay Using iTopia EDS
- Microtiter 96 well plates containing HLA class I MHC monomer loaded with the human β2-microglobulin and a “placeholder” peptide were used to evaluate peptide binding, affinity, and off-rate.
- The 502 nectin4 nonapeptides were first evaluated for their ability to bind to each MHC molecule in the peptide binding assay. In this assay, the placeholder peptides were stripped from the MHC class I monomer complexes coated on plastic, which leaves the MHC class I heavy chain available as a binding partner for candidate peptides in the presence of human β2-microglobulin.
- Peptide binding was performed at 21° C. for 18 h. Revelation was done using an anti HLA-ABC-FITC mAb that binds to refolded MHC complex conformation. The relative fluorescent intensity was read using a fluorimeter (Molecular Devices, SpectraMax Gemini, Sunnyvale, Calif., USA).
- Peptides with a binding >30% of the positive control peptide were selected as “binder” and subsequently analyzed for affinity (ED50) and off-rate (T1/2).
- Off-Rate Assay
- This assay evaluates the dissociation rate of “binder” peptides as a function of time. As for binding assay, peptides were incubated with MHC class I monomer at 21° C. for 18 h. Plates were then incubated at 37° C. and the MHC classI/peptide/β2-microglobulin complex was measured at 0.5, 1, 1.5, 2, 4, 6, 8 hours under agitation. The t1/2 value corresponds to the time in hours required to reach a 50% reduction of fluorescence intensity, i.e., a 50% of complex dissociation.
- Affinity Assay
- “Binder” peptides were incubated with MHC class I monomer at 21° C. for 18 h at concentrations ranging from 10-4 to 10-9 M. Affinity (ED50 value) is expressed as the peptide concentration that gives 50% of the optimal binding.
- iScore Calculation
- The iTopia system software was used to include, binding, off-rate (T1/2 value) and affinity (ED50 value) data collected for each peptide, in a multiparametric score called iScore. The corresponding graphs were generated using the GraphPad Prism®. Peptides with iScore >0.50 were considered as good candidates for HLA A*0201 binding.
- Cellular Binding Assay
- The CEM.T2 cell line (T2) is defective in the processing of proteins for presentation by MHC class I molecules. This cell line expresses HLA A*0201 but is deficient for TAP transporter. T2 is classically used to assess the Peptide/HLA-A*0201 Complex Stability[H. W. Nijman et al., 1993]
- For HLA-A2*0201 stabilization, T2 cells (2×105/well) were incubated in serum-free RPMI (Gibco®-France) with 100 μM of selected peptide, at 37° C. for 4 h. Cells were washed two times with PBS supplemented with 1% BSA and stained with fluorescein isothiocyanate-conjugated anti HLA-A2 (Clone BB7.2) (BD Bioscience Pharmingen-France-) at 4° C. for 45 min. After 3 washes, cells were fixed in PBS supplemented with 2% paraformaldehyde and analyzed by FACS (FACScan, BD Bioscience). The percentage of peptide binding was calculated as follows:
-
% Binding={(MFI peptide sample−MFI Neg control)/(MFI Pos control−MFI Neg control)}×100 - The peptide FLPSDFFPSV from Hepatitis B Virus [I. A. Doytchinova et al., 2004] was used as positive control peptide. Negative control was done without peptide.
- Cellular Dissociation Assay
- After HLA-A2*0201 stabilization with peptides at 37° C. for 4 h, T2 cells were incubated for 1 h, in serum-free RPMI containing Brefeldin A (10 μg/ml), an inhibitor of the transport of secretory and lysosomal proteins [G. J. Strous et al., 1993]. After 3 washes, T2 cells were incubated for 3 h in serum-free RPMI at 37° C. Binding was then measured by FACS and after 4 h incubation. Percentage of Residual Binding (% RB) was calculated as follows:
-
- Multimer Production
- Recombinant HLA-A*0201 molecules were folded in vitro with β2-microglobulin and nectin4 peptides and the EBV lytic cycle antigen BMLF1 peptide; VSDGGPNLY [M. DiBrino, et el., 1993]. Purification was achieved by gel fitration. Biotinylated tetramers were then labeled with either Extravidin-PE (Sigma, St Louis, Mont., USA) for the HLA-A2/Nectin4 multimers, or streptavidin-APC (Molecular Probes, Eugen, Oreg., USA) for the HLA-A2/EBV multimer control.
- Generation and Stimulation of Dendritic Cells
- PBMC from HLA-A2+ healthy volunteers were isolated by Ficoll-Plaque density gradient centrifugation. To generate autologous dendritic cells. PBMC were left to adhere for 1 h at 37° C. in culture flasks in RPMI 1640 supplemented with L-Arginine, L-Asparagine L-Glutamine (AAG), 1% streptomycin/penicillin and 10% FBS (complete RPMI medium). Non-adherent cells were removed and cultivated in IMDM supplemented with AAG, 1% streptomycin/penicillin, 10% human serum and IL-2 (5 U/ml) for 6 days. Adherent-cells were cultured in presence of GM-CSF (70 ng/ml) and IL-4 (200 U/ml) in complete RPMI medium. Cultures were fed on
days - Autologous monocyte-derived immature dendritic cells were incubated for 6 h with 10 μg/ml of a nectin4 peptide pool comprising LLASFTGRC (Pep No: 21), ALLHSKYGL (Pep No: 80), VLVPPLPSL (Pep No: 145), VVVGVIAAL (Pep No: 351), IL-4 (200 U/ml), GM-CSF (70 ng/ml), in presence of 1 μg/ml of Immucytal® granulare (Pierre Fabre Medicament Production, Gien, France) and 500 U/ml of INF-γ (R&D Systems). Dendritic cells were used to sustain activation of sorted lymphocytes.
- Isolation of CTL Populations
- Non-adherent cells (10×108 cells/ml) were incubated for 15 min at room temperature with HLA-A2 multimers loaded with Nectin4 peptides (20 nM).
- Multimer-labeled cells were incubated at 4° C. with anti-PE microbeads as recommended by the manufacturer (Miltenyi Biotec, Bergisch-Gladbach, Germany). After three washes, cells were magnetically sorted by AUTOMACS™ (Miltenyi Biotec). Efficacy of cell sorting was measured on a FACS CANTO™ II (Becton-Dickinson, Calif., USA). Sorted cells were incubated in 96 U-bottomed plates (2×104/200 μl) in IMDM medium containing IL-2 (20 U/ml), IL-7 (10 ng/ml) and 1.104 peptide pulsed irradiated autologous dendritic cells [S. Ottaviani, et al., 2005].
- Cytotoxicity Assay
- CTL cells were tested for cytolytic activity against the indicated target cells in a 4
h 51 Cr-release assay as previously described [C. Bottino et al., 2001]. The E/T ratios are indicated in the text. - Results
- Identification of Nectin4 Peptides that Bind MHC Class I Alleles.
- Nectin4 protein is a 510 aminoacids long protein. Screening of 502 nectin4 nonapeptides, spanning the entire sequence, was carried out on 8 different alleles (HLA-A*0101; HLA-A*0201; HLA-A*0301; HLA-A*1101; HLA-A*2402; HLA-A*0702; HLA-B*0801; HLA-B*1501) using the iTopia EDS. Peptide binding was analyzed according to manufacturer recommendations, i.e., with an arbitrary cut-off of 30% relative to the binding of allele specific control peptides. The number of positive peptides over 502 tested was represented for each allele in
FIG. 1 . We identified 5 HLA-A*0101, 130 HLA-A*0201, 24 HLA-A*0301, 38HLA-A*1101, 77 HLA-A*2402, 28 HLA-B*0702, 14 HLA-B*0801, 40 HLA-B*1501 binding peptides. Percentage of binding peptides ranged from 1% for HLA-A*0101 to 25% for HLA-A* 0201. Interestingly, we found that the greatest rates of peptides binding are in HLA-A*0201, HLA-A*2402 and HLA-B*1501 with respectively 130, 77, 40 positive peptides. These alleles have the similar binding motif. We decided to focus our study on HLA-A*0201 which represents the most frequent allele in US and Caucasian populations. As shown, inFIG. 1 , we found 130 nectin4 peptides with relative binding affinity higher than 30% of HLA-A*0201 positive control peptides. In order to select the best “binders”, the cut-off value was increased to 50% and 63 peptides were selected for the study. - Determination of Off-Rate Stability and Binding Affinity of the Selected Nectin4 Peptides.
- Analysis of binding affinity revealed that the
peptides FIG. 2A ) and better than the selected reference TAA peptides (FIG. 2B ). Indeed, over a peptide concentration ranging from 10-4 to 10-9 M, the estimated dose to reach 50% maximal binding (ED50) was around 10-7 M for these three peptides. - The relative stability of each complex was evaluated for a period of 8 h as described in material and methods. Off-rate stability was determined by measuring the dissociation time of the complex (t1/2). Three groups were found according to the t1/2 value. Among the 63 peptides, 16 have a t1/2>4 h, 19 a t1/2 between 2 h and 4 h, and 28 a t1/2<2 h. Decay curves are represented in
FIGS. 2C and 2D . t1/2 of five representative nectin4 peptides is showed and compared with the positive control peptide (POS) (FIG. 2C ) and the reference peptides listed in table 1 (FIG. 2D ). Among the 16 peptides with a t1/2 greater than 4 h, we found 3 nectin4 peptides (21, 80, 145) with a t1/2 over 6 hours. These values are close to the t1/2 of the positive control peptide and thereference peptides 513, 517, 519 (FIGS. 2C and 2D ). Peptide 351 (t1/2=3.4 h) and peptide 229 (t1/2=1.7 h) represent peptides with intermediate and low off-rate stability, respectively. - The iScore is dedicated to define the overall peptide binding properties to HLA alleles. This multiparametric analysis includes binding, off-rate and affinity of the peptide/HLA complex. The 63 peptides studied for HLA-A*0201 were classified in three groups according to manufacturer recommendations: the first group including 23 peptides with a low iScore ≦0.25; the second group including 18 peptides with a iScore between 0.25 and 0.50; the third group includes 22 peptides with an iScore ≧0.50. These 22 Nectin4 peptides can be considered as “good binders” (Table 2).
- T2 Cell Binding and Dissociation Assay.
- Because T2 cells lack TAP molecules, the HLA-A*0201 class I level on the cell surface of T2 cells is low. In the presence of binding peptides, HLA-A*0201 class I is stabilized, leading to up-regulation on the cell surface. This assay is highly relevant to peptide association with MHC class I molecule. However, this assay cannot be used for large screening. For this reason, we first restricted analysis on the 22 HLA-A*0201
class 1 binding peptides selected from iTopia assay (Table 2). As shown inFIG. 3A , the peptide 145 (white histogram) leads to increase the HLA-A*0201 class I level on T2 cells. The peptide 122, with a low iScore, does not increase HLA level on T2 cells (FIG. 3A , grey histogram). Positive control HBV peptide stabilized as well as peptide 145 (FIG. 3B , white histogram). In addition, dissociation assay was performed in the presence of Brefeldin A as described in material and methods. This assay is exemplified inFIGS. 3C and 3D forpeptide 145 and control HBV peptide, respectively. Among the 22 peptide tested,peptides - Integration of Overall Results: Ranking of Nectin4 Epitopes.
- Table 3 presents the different score related to the 22 selected peptides i.e.the iScore obtained with iTopia EDS, the T2 assay results that integrate T2 binding and T2 dissociation results and the SYFPEITHI and BIMAS score.
- Overall ranking of each peptide according to iTopia and cellular assays (F-Score) is shown in table 4. Ranking also includes control reference peptides presented in table 1.
Peptides - Generation and Detection of CTL Clones with HLA-A*0201 Tetramers Folded with Nectin4 Peptides
- According to the above results, we then developed an approach to characterize functional anti-nectin4 CTL from PBMC of normal donors. Phycoerythrin (PE) labeled HLA-A*0201/nectin4 tetramers were used to select specific CTL by immuno-magnetic cell sortings. After 21 days of culture, cells were screened with PE labeled tetramers (for example see
FIGS. 4A and 4B ). Tetramer-positive cells were tested for their capacity to kill nectin4 expressing tumor cells. Four out of five peptides selected and presented in table 4 were tested (80, 351, 145, 21). We used the MDA-MB-231 breast carcinoma cell line, which is HLA-A*0201 and does not express nectin4 as well as the MDA-MB-231 cell line transfected with Nectin4 plasmid. All the CTL isolated from the different tetramer/peptide were able to lyse the cell line when loaded with the respective peptides (see exampleFIG. 4C ). Among the five different CTL, only the CTL isolated from HLA-A2/nectin4-145 peptide were able to kill the MDA-MB-231 cell line expressing nectin4 but not the wild-type MDA-MB-231 cells (FIG. 4D ). These results lead to the identification of a naturally processed and HLA-A2 presented nectin4 peptide recognized by CD8+ T lymphocytes.Peptide 145 sequence (VLVPPLPSL) is located at the beginning of the second Ig-like domain (FIG. 5A ). Interestingly, iTopia EDS and SYFPEITHI analyzes highlight that this peptide behave as a “strong binder” candidate for HLA-A*0201, HLA-A*2402, HLA-B*1501 (FIG. 5B ). This is of first importance regarding its potential use in clinical trials. - Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.
- A. Takano et al., “Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer,” Cancer Research, vol. 69, no. 16, p. 6694-6703, Aoû. 2009.
- C. Bottino et al., “NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease,” The Journal of Experimental Medicine, vol. 194, no. 3, p. 235-246. 2001.
- D. Pende et al., “PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis,” Molecular Immunology, vol. 42, no. 4, p. 463-469, Fey. 2005.
- F. Brancati et al., “Mutations in PVRL4, encoding cell adhesion molecule nectin-4, cause ectodermal dysplasia-syndactyly syndrome,” American Journal of Human Genetics, vol. 87, no. 2, p. 265-273, Aoû. 2010.
- G. J. Strous, P. van Kerkhof, G. van Meer, S. Rijnboutt, et W. Stoorvogel, “Differential effects of brefeldin A on transport of secretory and lysosomal proteins,” The Journal of Biological Chemistry, vol. 268, no. 4, p. 2341-2347, Fey. 1993.
- H. W. Nijman et al., “Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes,” European Journal of Immunology, vol. 23, no. 6, p. 1215-1219, Juin. 1993.
- I. A. Doytchinova, V. A. Walshe, N. A. Jones, S. E. Gloster, P. Borrow, et D. R. Flower, “Coupling in silico and in vitro analysis of peptide-MHC binding: a bioinformatic approach enabling prediction of superbinding peptides and anchorless epitopes,” Journal of Immunology (Baltimore, Md.: 1950), vol. 172, no. 12, p. 7495-7502, Juin. 2004.
- M. DiBrino, T. Tsuchida, R. V. Turner, K. C. Parker, J. E. Coligan, et W. E. Biddison, “HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs,” Journal of Immunology (Baltimore, Md.: 1950), vol. 151, no. 11, p. 5930-5935, December 1993.
- M. Kuramochi et al., “TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer,” Nature Genetics, vol. 27, no. 4, p. 427-430, Avr. 2001.
- N. Reymond, S. Fabre, E. Lecocq, J. Adelaide, P. Dubreuil, et M. Lopez, “Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction,” The Journal of Biological Chemistry, vol. 276, no. 46, p. 43205-43215, November 2001.
- N. Reymond et al., “DNAM-1 and PVR regulate monocyte migration through endothelial junctions,” The Journal of Experimental Medicine, vol. 199, no. 10, p. 1331-1341. Mai. 2004.
- S. Fabre-Lafay et al., “Nectin-4 is a new histological and serological tumor associated marker for breast cancer,” BMC Cancer, vol. 7, p. 73, 2007.
- S. Fabre-Lafay, S. Garrido-Urbani, N. Reymond, A. Gonçalves, P. Dubreuil, et M. Lopez, “Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17,” The Journal of Biological Chemistry, vol. 280, no. 20, p. 19543-19550. Mai. 2005.
- S. Fabre et al., “Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin4 bind to the predicted C—C—C″-D beta-strands of the nectin1 V domain,” The Journal of Biological Chemistry, vol. 277, no. 30, p. 27006-27013, Juil. 2002.
- S. Ottaviani, Y. Zhang, T. Boon, et P. van der Bruggen, “A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells,” Cancer Immunology, Immunotherapy: CII, vol. 54, no. 12, p. 1214-1220, December 2005.
- Y. Takai et H. Nakanishi, “Nectin and afadin: novel organizers of intercellular junctions,” Journal of Cell Science, vol. 116. no. 1, p. 17-27, January 2003.
- Y. Takai, W. Ikeda, H. Ogita, et Y. Rikitake, “The immunoglobulin-like cell adhesion molecule nectin and its associated protein afadin,” Annual Review of Cell and Developmental Biology, vol. 24, p. 309-342, 2008.
- Y. Takai, J. Miyoshi, W. Ikeda, et H. Ogita, “Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation,” Nature Reviews. Molecular Cell Biology, vol. 9, no. 8, p. 603-615, Aoû. 2008.
Claims (4)
1-11. (canceled)
12. A method for producing genetically modified T lymphocytes, said method comprising the steps of:
(a) stimulating PBMCs or tumor infiltrating lymphocytes obtained from a subject with at least one antigen peptide, wherein said antigen peptide comprises an amino acid motif having an amino acid sequence:
wherein the amino acid sequence of the amino acid motif may differ from VLVPPLPSL by 1, 2 or 3 amino acids,
(b) enriching the population of T lymphocytes specific for the antigen peptide(s) used in (a), and
(c) optionally cloning said population of T lymphocytes specific for the antigen peptide(s) used in (a).
13-14. (canceled)
15. A method of treating cancer in a subject in need thereof, comprising the steps of
(a) stimulating PBMCs or tumor infiltrating lymphocytes obtained from the subject with at least one antigen peptide, wherein said antigen peptide comprises an amino acid motif having an amino acid sequence:
wherein the amino acid sequence of the amino acid motif may differ from VLVPPLPSL by 1, 2 or 3 amino acids,
(b) enriching the population of genetically modified T lymphocytes specific for the antigen peptide(s) used in (a),
(c) optionally cloning said population of genetically modified T lymphocytes specific for the antigen peptide(s) used in (a), and
(d) administering to the subject a therapeutically effective amount of a composition for adoptive therapy comprising the genetically modified T lymphocytes produced in (b) or (c).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/963,308 US20160331818A1 (en) | 2011-06-01 | 2015-12-09 | Novel antigen peptide and uses thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305677.4 | 2011-06-01 | ||
EP11305677 | 2011-06-01 | ||
PCT/EP2012/060224 WO2012164004A1 (en) | 2011-06-01 | 2012-05-31 | Novel antigen peptide and uses thereof |
US201414122937A | 2014-02-18 | 2014-02-18 | |
US14/963,308 US20160331818A1 (en) | 2011-06-01 | 2015-12-09 | Novel antigen peptide and uses thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/122,937 Division US9266922B2 (en) | 2011-06-01 | 2012-05-31 | Antigen peptide and uses thereof |
PCT/EP2012/060224 Division WO2012164004A1 (en) | 2011-06-01 | 2012-05-31 | Novel antigen peptide and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160331818A1 true US20160331818A1 (en) | 2016-11-17 |
Family
ID=46197273
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/122,937 Expired - Fee Related US9266922B2 (en) | 2011-06-01 | 2012-05-31 | Antigen peptide and uses thereof |
US14/963,308 Abandoned US20160331818A1 (en) | 2011-06-01 | 2015-12-09 | Novel antigen peptide and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/122,937 Expired - Fee Related US9266922B2 (en) | 2011-06-01 | 2012-05-31 | Antigen peptide and uses thereof |
Country Status (3)
Country | Link |
---|---|
US (2) | US9266922B2 (en) |
EP (1) | EP2714730A1 (en) |
WO (1) | WO2012164004A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201601868D0 (en) * | 2016-02-02 | 2016-03-16 | Lytix Biopharma As | Methods |
WO2017194170A1 (en) * | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0563485A1 (en) | 1992-03-30 | 1993-10-06 | Schering-Plough | In vitro generation of human dendritic cells and uses thereof |
WO1993020185A1 (en) | 1992-04-01 | 1993-10-14 | Steinman Ralph M | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
FR2798128B1 (en) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | MEANS OF DETECTION AND PURIFICATION OF T CD8 + LYMPHOCYTE POPULATIONS SPECIFIC TO PEPTIDES PRESENT IN THE HLA CONTEXT |
US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
US20090214517A1 (en) | 2004-07-27 | 2009-08-27 | Justin Wong | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease |
-
2012
- 2012-05-31 US US14/122,937 patent/US9266922B2/en not_active Expired - Fee Related
- 2012-05-31 WO PCT/EP2012/060224 patent/WO2012164004A1/en active Application Filing
- 2012-05-31 EP EP12724636.1A patent/EP2714730A1/en not_active Withdrawn
-
2015
- 2015-12-09 US US14/963,308 patent/US20160331818A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20140178394A1 (en) | 2014-06-26 |
WO2012164004A1 (en) | 2012-12-06 |
EP2714730A1 (en) | 2014-04-09 |
US9266922B2 (en) | 2016-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101386355B1 (en) | Tumor-associated peptides binding promiscuously to human leukocyte antigen(hla) class ii molecules | |
RU2721574C2 (en) | Vaccine composition for malignant tumor | |
JP2019502360A (en) | Novel peptides and peptide combinations for use in immunotherapy against CLL and other cancers | |
US20080107668A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
EP2043679A2 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
KR101744514B1 (en) | Neil3 peptides and vaccines including the same | |
US10765729B2 (en) | Tumor antigen peptide | |
JP6960179B2 (en) | Tumor antigen peptide | |
US20050277161A1 (en) | Phosphopeptide antigens associated with MHC molecules | |
JP2006518982A (en) | MHCII binding peptide | |
US20160331818A1 (en) | Novel antigen peptide and uses thereof | |
JP4365405B2 (en) | Tumor associated peptides that bind to MHC molecules | |
KR101765452B1 (en) | Cdc45l peptides and vaccines including the same | |
AU2012380681A1 (en) | Novel melanoma antigen peptide and uses thereof | |
TW201138803A (en) | ECT2 peptides and vaccines including the same | |
JP5736333B2 (en) | Tumor-associated peptide that binds to human leukocyte antibody (HLA) class II molecules indiscriminately | |
JP2013176367A (en) | Vegfr1-originated peptide and vaccine containing the same | |
JP5736334B2 (en) | Tumor-associated peptide that binds to human leukocyte antibody (HLA) class II molecules indiscriminately | |
JP2013176366A (en) | Vegfr1-originated peptide and vaccine containing the same | |
AU1493200A (en) | In vivo activation of tumor-specific cytotoxic T cells | |
NZ701000A (en) | Novel melanoma antigen peptide and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |